United Services Automobile Association Reduces Holdings in Audentes Therapeutics Inc (NASDAQ:BOLD)

United Services Automobile Association cut its stake in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 13.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,531 shares of the biotechnology company’s stock after selling 7,240 shares during the quarter. United Services Automobile Association owned 0.10% of Audentes Therapeutics worth $1,800,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Meeder Asset Management Inc. boosted its holdings in Audentes Therapeutics by 578.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 619 shares during the period. Aperio Group LLC purchased a new stake in Audentes Therapeutics in the 2nd quarter worth approximately $46,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Audentes Therapeutics by 50.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock worth $113,000 after buying an additional 1,005 shares during the period. Bank of Montreal Can lifted its holdings in Audentes Therapeutics by 810.4% in the 2nd quarter. Bank of Montreal Can now owns 4,106 shares of the biotechnology company’s stock worth $155,000 after buying an additional 3,655 shares during the period. Finally, Algert Global LLC purchased a new stake in Audentes Therapeutics in the 2nd quarter worth approximately $250,000. Institutional investors own 98.21% of the company’s stock.

Several research firms have weighed in on BOLD. Mizuho reiterated a “buy” rating and issued a $45.00 price objective on shares of Audentes Therapeutics in a report on Wednesday, August 7th. Chardan Capital restated a “buy” rating and issued a $50.00 target price on shares of Audentes Therapeutics in a research note on Sunday. William Blair restated a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, August 7th. BidaskClub cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 27th. Finally, Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research note on Tuesday. Four equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $39.35.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 20,000 shares of Audentes Therapeutics stock in a transaction on Monday, August 12th. The stock was sold at an average price of $34.04, for a total value of $680,800.00. Following the completion of the sale, the chief executive officer now owns 135,368 shares of the company’s stock, valued at approximately $4,607,926.72. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 10,000 shares of Audentes Therapeutics stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total value of $321,600.00. Following the completion of the sale, the director now directly owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The disclosure for this sale can be found here. 5.30% of the stock is owned by company insiders.

BOLD stock opened at $27.80 on Wednesday. Audentes Therapeutics Inc has a twelve month low of $17.95 and a twelve month high of $41.65. The firm has a market cap of $1.24 billion, a PE ratio of -8.18 and a beta of 1.79. The business has a 50 day moving average of $30.50 and a 200 day moving average of $36.05.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.08) by $0.07. During the same period in the prior year, the business posted ($0.85) EPS. On average, equities research analysts predict that Audentes Therapeutics Inc will post -4.29 earnings per share for the current year.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: Are sell-side analysts objective?

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.